IMAGINE-TBM is an international multisite randomized, open label clinical trial evaluating a six-month regimen of high dose rifampin, high dose isoniazid, linezolid, and pyrazinamide versus a standard nine-month regimen for the treatment of adults and adolescents with tuberculous meningitis. This AIDS Clinical Trials Group (ACTG) trial sponsored by DAIDS is slated to open to enrollment in 2021.
Region:
Multinational
category research:
Neuro-Infectious Diseases/Neuro-Immunology
BALANCE Investigators: